Chemours (NYSE:CC) Cut to “Strong Sell” at Zacks Research

Zacks Research cut shares of Chemours (NYSE:CC) from a hold rating to a strong sell rating in a research note published on Wednesday morning,Zacks reports.

CC has been the subject of a number of other research reports. UBS Group decreased their price target on shares of Chemours from $16.00 to $15.00 and set a “neutral” rating for the company in a research note on Wednesday. Morgan Stanley set a $18.00 target price on shares of Chemours in a report on Monday, August 10th. Royal Bank Of Canada lowered Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price target on the stock. in a report on Tuesday, October 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Chemours in a research report on Tuesday. Finally, BMO Capital Markets dropped their price target on Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a research report on Thursday, August 13th. Three research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $17.45.

Chemours Stock Performance

Shares of Chemours stock traded down $0.03 on Wednesday, hitting $12.72. The stock had a trading volume of 3,698,087 shares, compared to its average volume of 2,310,033. Chemours has a 52-week low of $10.44 and a 52-week high of $28.67. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -12.47 and a beta of 1.47. The company’s 50 day moving average price is $13.96 and its 200 day moving average price is $18.22.

Chemours (NYSE:CC) last released its quarterly earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 EPS for the quarter, missing the consensus estimate of $0.26 by ($0.05). The firm had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.53 billion. Chemours had a positive return on equity of 78.76% and a negative net margin of 2.64%. The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the firm earned $0.40 EPS. On average, research analysts anticipate that Chemours will post 0.82 EPS for the current year.

Chemours Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Shareholders of record on Monday, November 16th will be given a dividend of $0.0875 per share. The ex-dividend date is Monday, November 16th. This represents a $0.35 annualized dividend and a yield of 2.8%. Chemours’s payout ratio is presently -34.31%.

Insider Buying and Selling

In other Chemours news, insider Calderon Gerardo Familiar purchased 1,935 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were purchased at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the purchase, the insider directly owned 58,547 shares in the company, valued at $909,234.91. This represents a 3.42% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Denise Dignam acquired 3,378 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were acquired at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the acquisition, the chief executive officer directly owned 339,916 shares of the company’s stock, valued at $5,081,744.20. This trade represents a 1.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On Chemours

A number of hedge funds and other institutional investors have recently bought and sold shares of CC. Deutsche Bank AG purchased a new position in shares of Chemours in the 2nd quarter valued at about $3,291,000. The Manufacturers Life Insurance Company purchased a new stake in Chemours during the second quarter worth about $1,522,000. Jefferies Financial Group Inc. purchased a new stake in Chemours during the second quarter worth about $15,996,000. BlackRock Inc. purchased a new stake in Chemours during the second quarter worth about $477,769,000. Finally, Old West Investment Management LLC acquired a new position in Chemours during the second quarter worth about $7,152,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

Key Headlines Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions aimed at managing heat in AI data centers, with the company touting improved efficiency and lower water use. The product could help it benefit from growing data-center demand. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
• Neutral Sentiment: Barclays maintained its Hold rating. Other analyst views are mixed, while UBS lowered its price target to $15 and kept a Neutral rating. Article: Barclays Keeps Their Hold Rating on Chemours
• Negative Sentiment: Zacks Research downgraded CC from Hold to Strong Sell, adding to concerns about analyst sentiment. Zacks Research rating information
• Negative Sentiment: Multiple law firms publicized a securities class action filed against Chemours and certain officers, covering purchases from February 20 through August 4, 2026. The suit alleges securities-law violations, including claims related to 2026 EBITDA guidance and refrigerant sales pulled forward by customer prebuying; these allegations have not been proven. Investors have until December 7 to seek lead-plaintiff status. The repeated alerts concern the same case, rather than separate lawsuits. Article: Lawsuit deadline and allegations regarding 2026 EBITDA guidance

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.